2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab
Prof Walter Weder speaks to ecancer at BGICC 2023 about developments in surgery for early stage lung cancer.
He outlines two studies from the past few years that have significantly impacted surgical approaches.
Prof Weder summarises that the results showed the overall survival was 3% better for lung cancer patients who received a segmentectomy versus a lobectomy.
My second talk was on surgery for early stage lung cancer and in the past three years two very important studies came out addressing the issue of small-sized tumours located in the periphery – do they always require a complete lobectomy or can they be resected by a segmentectomy? The tumour size was limited to 2cm and the first study from the Japanese group showed that the overall survival was similar, in fact 3% better for segmentectomy compared to lobectomy, which was a surprise. We thought it was the other way around and we cannot really explain why segmentectomy is slightly better. The local recurrence rate is higher and the functional difference between segmentectomy and lobectomy is relatively small, it was 3%.
These data were confirmed by a multicentre study coming from the United States showing no difference in overall survival and disease free survival comparing sublobar resection to lobectomy. This influences the decision-making process for these small tumours in the future, that in general sublobar resection and segmentectomy is enough and we don’t have to perform a lobectomy. However, certain tumours are not ideally located for a segmentectomy and lobectomy is still possible to be performed.
2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab
Osimertinib plus chemotherapy shows superior results versus osimertinib alone for EGFR-mutated advanced lung cancer
The advantages of IORT for early breast cancer treatment
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC
Neoadjuvant nivolumab plus chemotherapy continues to provide long-term clinical benefit in patients with resectable NSCLC
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC
Final data from phase II study of eftilagimod alpha and pembro in PD-1/PD-L1 inhibitors resistant second line metastatic NSCLC